Code intelligence

K76.0 reimbursement alerts

Policy changes, MAC LCD updates, and CMS guidance matched to code K76.0.

Elevated code riskView ICD-10 detail

Signal breakdown

8 shown · 8 total in platform

Risk: Elevated

Critical

High

50%

Routine

50%

Low

New this month

—

alerts added in last 30 days

Effective soon

—

no upcoming deadlines

LCD L40187 (Notice Ends 08/09/2026): MolDX: Biomarker Testing in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis — Palmetto GBA

Policy LCD-L40187 · Clinical Laboratory

Routine

New MolDX LCD for MASLD/MASH biomarker tests effective Aug 2026.

View alert

LCD L40199 (Notice Ends 08/09/2026): MolDX: Biomarker Testing in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis — CGS Administrators

Policy LCD-L40199 · Clinical Laboratory

Routine

New MolDX LCD for MASLD/MASH biomarker tests effective Aug 2026.

View alert

LCD L40197 (Notice Ends 08/09/2026): MolDX: Biomarker Testing in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis — Noridian

Policy LCD-L40197 · Clinical Laboratory

Routine

New LCD governs MASLD/MASH biomarker testing starting Aug 2026.

View alert

LCD L40272 (Notice Ends 08/09/2026): MolDX: Biomarker Testing in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis — WPS

Policy LCD-L40272 · Clinical Laboratory

Routine

New MolDX biomarker LCD for MASLD/MASH liver disease effective Aug 2026.

View alert

Proposed LCD DL40199: MolDX: Biomarker Testing for Risk Stratification in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis — CGS

Policy LCD-DL40199 · Gastroenterology

High

New LCD may affect billing for liver disease biomarker testing.

View alert

Proposed LCD DL40197: MolDX: Biomarker Testing for Risk Stratification in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis — Noridian

Policy LCD-DL40197 · Gastroenterology

High

Impact on billing for liver disease biomarker testing.

View alert

Proposed LCD DL40187: MolDX: Biomarker Testing for Risk Stratification in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis — Palmetto GBA

Policy LCD-DL40187 · Gastroenterology

High

New LCD for biomarker testing in liver disease proposed.

View alert

Proposed LCD DL40272: MolDX: Biomarker Testing for Risk Stratification in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis — WPS

Policy LCD-DL40272 · Gastroenterology

High

Impact of new LCD on liver disease biomarker testing billing.

View alert

Audit documentation

Building an audit file that includes K76.0?

The Tripwire Audit Pack exports 12 months of Clinical Laboratory policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.

Get the Clinical Laboratory audit pack — $349One-time purchase · not a subscription